Evidence map›Paper›PMID 41234830›Full record

ArticleTranslational cancer research2025

Unveiling

Shuai Cao, Yucheng Zhao, Lu Zhang, Junhong Zhuang, Peiqi Jia, Dongmei Han, Hao Jin, Liming Xu

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuai CaoDepartment of Radiotherapy, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Yucheng ZhaoHepatobiliary and Vascular Surgery, People's Hospital Affiliated to Shandong First Medical University, Jinan, China.
Lu ZhangClinical Laboratory, People's Hospital Affiliated to Shandong First Medical University, Jinan, China.
Junhong ZhuangDepartment of Radiotherapy, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Peiqi JiaClinical Laboratory, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Dongmei HanCenter for Precision Cancer Medicine and Translational Research, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.ORCID https://orcid.org/0000-0002-5074-4900
Hao JinCenter for Precision Cancer Medicine and Translational Research, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.ORCID https://orcid.org/0000-0002-4878-118X
Liming XuDepartment of Radiotherapy, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Endometrial carcinoma (EC) is a prevalent gynecological malignancy with diverse genetic underpinnings. This study aimed to elucidate the prognostic significance of genetic mutations, particularly Methods: Clinical and RNAseq data were acquired from cBioPortal and The Cancer Genome Atlas (TCGA). These data were utilized for prognostic analysis. Immune landscape analysis using single sample Gene Set Enrichment Analysis (ssGSEA) revealed enhanced infiltration of immune cells in Results: We identified Conclusions: Our study highlighted the potential of

Indexed as

Endometrial carcinoma (EC)nomogram modelPIK3CA mutationprognosis and immune infiltration

Identifiers

PMID41234830
PMCPMC12605787

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.